Explore Illumina, Inc.'s Q2 2025 financial report showcasing a recovery in net income, strategic R&D investments, and ongoing challenges. Recommendation: Hold.
Explore Illumina, Inc.'s 8-K filing from July 31, 2025, including vital company info, stock data, and structured reporting insights.
Explore Illumina, Inc.'s latest 8-K filing detailing significant events on June 22, 2025. Stay informed with crucial insights for investors and analysts.
Explore Illumina, Inc.'s 8-K filing from May 21, 2025, detailing crucial, time-sensitive updates for investors.
Explore Illumina's Q1 2025 financial performance, revealing $947M revenue, $131M net income, and strategic insights post-GRAIL spin-off. Key trends and future outlook included.
Discover crucial updates from Illumina, Inc. in their 8-K report filed on May 8, 2025, impacting shareholders and stakeholders.
Explore the current challenges in the biotech sector and discover resilient companies like Amgen, Gilead, Moderna, Illumina, and Vertex that present promising investment opportunities.
Explore Illumina, Inc.'s 8-K report filed on March 10, 2025, detailing significant corporate events. Key stock info and SEC details included.
Explore Illumina, Inc.'s March 25, 2025, 8-K report detailing significant corporate changes and stock information. Essential for investors and analysts monitoring regulatory compliance.
Explore Illumina, Inc.'s latest 8-K filing report detailing important updates and regulatory information effective March 24, 2025. Stay informed on ILMN's corporate developments!
Explore Illumina, Inc.'s Q4 2024 financial results, revealing $3.99B revenue, $1.22B net loss, and GRAIL segment challenges. Key insights and future outlook provided.
Explore Illumina, Inc.'s 8-K/A filing detailing amendments, future reporting dates, and SEC compliance. Stay informed about stock updates and corporate transparency.